Undisclosed novel target

The term "Undisclosed novel target" is a placeholder designation used by biotechnology and pharmaceutical companies to refer to a specific biological molecule—such as a protein, enzyme, or receptor—that is the focus of a drug discovery or development program but whose identity has not been publicly revealed [1, 2]. This nomenclature is typically employed in press releases, financial filings, and early-stage pipeline descriptions to protect proprietary research and intellectual property during the competitive stages of drug development [5, 16]. For example, companies like Pheon Therapeutics, Immunic, and Synlogic have utilized this terminology for programs in oncology and inflammatory diseases [2, 3, 8]. Because the term does not refer to a single, specific biological entity, it lacks a defined molecular classification, biological function, or established role in disease [9, 10]. Consequently, it cannot be characterized by standard pharmacological parameters until the specific target is formally disclosed by the developer [12, 14]. Once a target is revealed, it is typically assigned a canonical name and classification based on its biological properties and therapeutic relevance.